Property:Results after intervention
This is a property of type Text.
S
Stauder et al. (1991): Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzyme +
Average tolerability by doctor: enzyme-arm: 1.57(0.88); control-arm: 1.38(0.86)
Average tolerability by patient: enzyme-arm: 1.75(1.13); control-arm: 1.41(0.86)
Therapy result by doctor: enzyme-arm: 1.94(0.79); control-arm : 1.22(0.54)
Therapy result by patient: enzyme-arm: 1.89(0.85); control-arm: 1.22(0.54) +
Stauder et al. (1991): Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzyme +
Mean onset in days of radiation side effects per arm
Ezyme-arm: 17.3(12.3)
Control-arm B: 15.6(7.7)
(p=NI)
Mean duration in days of radiation side effects per arm
Enzyme-arm: 12.8(9.7)
Control-arm: 24.6(14.2)
(p=NI)
Severity of side effects (score from 1 to 3) per arm:
Enzyme-Arm: 1.77(0.77)
Control-Arm: 1.88(0.62)
(p=NI)
The side effects in the enzyme-arm started later, were less severe and lasted for a shorter time compared to the side effects in the control arm. +
Stauder et al. (1991): Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzyme +
No radiation-related headaches and ulcerations occurred in either arm; vomiting symptoms and oedema only occurred in the control-arm; all other symptoms occurred in both arms, but less frequently and less intensively in the enzyme-arm than in the control-arm.
Deterioration of the general status in 5.5% of the enzyme-arm and in 11.4% of the control-arm, no changes of the general status in 94.5% of the enzyme-arm and 88.6% of the control-arm. +
Stauder et al. (1991): Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzyme +
Single doses: The average single radiation dose was approx. 8% higher in the enzyme-arm at the beginning and approx. 4% higher after 2 and 5 weeks than in the control-arm.
Total dose: After 2 weeks the total dose was about the same in both arms, after 5 weeks the difference between the enzyme-arm and the control-arm was about 16% more in the enzyme-arm. +
Stauder et al. (1991): Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzyme +
Patients from the enzyme-arm got 102 additional medications, patients from the control-arm got 125 additional medications (p=NI). The duration of taking the additional medication did not differ between the two arms. +
Stendell-Hollis et al. (2010): Green tea improves metabolic biomarkers, not weight or body composition: a pilot study in overweight breast cancer survivors +
The average body weight in the green tea arm was reduced by 1.2 kg compared to the baseline, whereas assignment to the placebo arm was associated with a slight rise in mean body weight of 0.2 kg over the same time period. These changes were not significant (p=0.23). +
Stendell-Hollis et al. (2010): Green tea improves metabolic biomarkers, not weight or body composition: a pilot study in overweight breast cancer survivors +
The BMI in the green tea arm was reduced by 0.5 kg/m<sup>2</sup> after 6 month, the body fat percentage by 0.6%, the BMI in the placebo arm remained the same after 6 month , body fat percentage increased slightly by 0.4%, but these differences were not significant (p=0.22 for BMI, p=0.21 for body fat). +
Stephenson et al. (2000): The Effects of Foot Reflexology on Anxiety and Pain in Patients With Breast and Lung Cancer. +
NA +
Stephenson et al. (2000): The Effects of Foot Reflexology on Anxiety and Pain in Patients With Breast and Lung Cancer. +
NA +
Stephenson et al. (2000): The Effects of Foot Reflexology on Anxiety and Pain in Patients With Breast and Lung Cancer. +
NA +
Stephenson et al. (2000): The Effects of Foot Reflexology on Anxiety and Pain in Patients With Breast and Lung Cancer. +
NA +
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
NA +
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
NA +
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
NA +
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
NA +